Home > Access to medicinal cannabis: meeting patient needs.

All-Party Parliamentary Group for Drug Policy Reform. (2016) Access to medicinal cannabis: meeting patient needs. London: All-Party Parliamentary Group for Drug Policy Reform. 47 p.

[img]
Preview
PDF (Access to medicinal cannabis)
830kB

Many jurisdictions across the world have either already introduced systems that allow lawful access to medicinal cannabis or are in the process of so doing. At least 11 European countries already ensure access to it including: Austria, the Czech Republic, Finland, Belgium, Germany, Italy, the Netherlands, Romania, Portugal and Switzerland. Twenty-four States in the USA also ensure access, with more states due to vote on the matter. Canada, Israel, Jamaica and many Latin American countries, including Uruguay, Chile and Colombia join the countries that allow access to cannabis for medicinal purposes.

However, the UK lags behind. Indeed, in the UK cannabis and its derivatives are listed under Schedule 1, the Schedule for dangerous drugs with no medicinal value. At the same time, the UK Government has approved nabiximols (trade name Sativex) and nabilone (trade name Cesamet), which seems irrational and contrary to the Government’s scheduling decision.

This issue matters to a substantial number of patients (and their families) across the UK. One estimate of current users of medicinal cannabis in the UK puts the figure at 30,000 daily. However, the campaign group End Our Pain (www.endourpain.org) puts the estimate at approaching 1,000,000 in total. This is based on the fact that Home Office figures put the number of UK cannabis takers (both recreational and medicinal) at 3,000,000, and figures from the USA suggest that approaching 1 in 3 will be for primarily medical reasons. If this figure seems high, it is interesting to note that Germany, which is currently introducing legislation to allow legal access to medicinal cannabis estimates that nearly 800,000 of its citizens may be eligible under their scheme.

Against this background, the APPG convened the most in-depth parliamentary inquiry into this issue ever undertaken. Alongside their inquiry, the APPG commissioned the most extensive review of evidence in the literature in modern times.


Item Type:Evidence resource
Publication Type:Report
Drug Type:Cannabis
Intervention Type:AOD disorder harm reduction
Date:September 2016
Pages:47 p.
Publisher:All-Party Parliamentary Group for Drug Policy Reform
Corporate Creators:All-Party Parliamentary Group for Drug Policy Reform
Place of Publication:London
EndNote:View
Related URLs:
Subjects:B Substances > Cannabis / Marijuana
G Health and disease > State of health > Physical health
J Health care, prevention and rehabilitation > Health care delivery
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > Europe > United Kingdom

Repository Staff Only: item control page